3 recruiting. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Refractory Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Refractory Head and Neck Squamous Cell Carcinoma trials Research Report on Refractory Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-26 |
| Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy - Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | University of California, Davis | 24 | 2023-12-07 | 2026-03-12 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma (1) · Chondrosarcoma (1) · Endometrial Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Melanoma (1) · Mouth Neoplasms (1) · Ovarian Neoplasms (1)
Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Carcinoma (2) · Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
pembrolizumab (2) · (225)Ac-DOTA-c(RGDyK) (1) · Bevacizumab (1) · Cetuximab (1) · Disulfides (1) · Immunoglobulin G (1) · Losartan (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Radiosurgery (1) · Specimen Handling (1) · Taxes (1) · capivasertib (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of California, Davis (1)
United States (3)
Shyam S.D. Rao, MD, PhD (1) · Siddharth Sheth (1) · Timothy A Yap, MD (1)
P30CA093373 (1), U10CA180821 (1)